Minimizing Neurological Side Effects with AEDs

Primary Recommendations

Levetiracetam is the preferred first-line AED when minimizing neurological side effects is the priority, followed closely by lamotrigine, as they are classified as non-enzyme-inducing AEDs with favorable tolerability profiles compared to older agents 1, 2
The National Comprehensive Cancer Network classifies levetiracetam as a non-enzyme-inducing AED that is generally better tolerated than other options, although specific details are not provided in the cited references 3

Phenytoin, carbamazepine, and phenobarbital should be avoided when minimizing neurological side effects is the goal, as they cause significant cognitive impairment, neuropsychiatric disorders, fatigue, and more pronounced ataxia and drowsiness 1, 2, 3
Carbamazepine specifically causes dizziness that may disturb daily activities, requiring bedtime dosing to minimize this effect 4

In brain tumor patients, non-enzyme-inducing AEDs (levetiracetam, lamotrigine) are strongly preferred to avoid interactions with chemotherapy, targeted therapies, and steroids 1, 2

The National Comprehensive Cancer Network classifies levetiracetam and valproic acid as non-enzyme-inducing AEDs, making them preferable when avoiding cytochrome P450-mediated drug interactions is critical 5
Phenytoin, phenobarbital, and carbamazepine should be avoided when possible due to significant effects on the cytochrome P450 system, which can alter metabolism of chemotherapeutic agents including irinotecan, gefitinib, erlotinib, and temsirolimus 5
In patients with brain tumors receiving chemotherapy, levetiracetam is generally better tolerated than valproic acid due to lower risk of hematologic toxicities, despite both being non-enzyme-inducing 6

In traumatic brain injury, phenytoin showed increased side effects and even worsening of neurological outcomes compared to other AEDs 7
Valproate showed worsening of neurological outcomes in some contexts, though it has a better neurological profile than phenytoin 7
Carbamazepine specifically causes dizziness that disturbs daily activities, requiring bedtime dosing to minimize this effect 8
In brain tumor patients receiving chemotherapy, the choice of AED becomes critical due to potential drug interactions and neurological toxicity 9